Ligand Pharmaceuticals (LGND) Q2 2025 earnings summary

Executive summary

• Q2 2025 revenue rose 15% year-over-year to $47.6 million, driven by a 57% increase in royalty revenue, notably from Ohtuvayre, Filspari, and Qarziba, and supported by Captisol sales.

• GAAP net income for Q2 2025 was $4.8 million, reversing a net loss of $51.9 million in Q2 2024; core adjusted net income grew to $32.0 million from $25.8 million.

• Major business developments included the Pelthos Therapeutics merger, commercial launch of Zelsuvmi, and Merck's $10 billion acquisition of Verona, accelerating Ohtuvayre's growth.

• Strategic investments included $40 million in Orchestra BioMed, $18 million in Pelthos, and a $44.3 million R&D charge for Castle Creek, expanding the royalty portfolio.

• Cash, cash equivalents, and short-term investments totaled $245 million as of June 30, 2025, with $450 million in deployable capital and no debt.

Financial highlights

• Q2 2025 royalties reached $36.4 million, up 57% year-over-year, led by Ohtuvayre, Filspari, Qarziba, and CAPVAXIVE.

• Captisol sales grew 10% to $8.3 million in Q2 2025.

• Contract revenue and other income declined to $2.9 million in Q2 2025 due to timing of partner milestones.

• Operating expenses increased due to headcount growth and Pelthos incubation, but are expected to decrease in H2 2025 after Pelthos deconsolidation.

• Six-month revenue increased 28% year-over-year to $93.0 million, with royalties up 51% and Captisol sales up 30%.

Outlook and guidance

• 2025 full-year revenue guidance raised to $200–$225 million (from $180–$200 million); adjusted EPS guidance increased to $6.70–$7.00 (from $6.00–$6.25).

• Royalty revenue guidance raised to $140–$150 million; Captisol sales expected at $35–$40 million.

• Long-term royalty receipts projected to grow at a 22% CAGR from 2024–2029, with further upward revisions possible.

• Sufficient liquidity and access to financing are expected to support ongoing operations and business initiatives.